House Values Action Team Chairman Robert Aderholt and Members’ Statement on FDA Approval of Chemical Abortion Pill

House Values Action Team Chairman Robert Aderholt and Members released the following statements after the FDA’s approval of a new generic abortion drug:

"The FDA’s approval of a new generic version of the abortion pill, mifepristone, endangers women’s health and disregards the value of life. Previously approved versions of this drug demonstrated dangerous side effects including life-threatening sepsis, infection and hemorrhaging. The FDA’s own fact sheet on mifepristone shows troubling rates of adverse events including hospitalization, blood transfusions, and even death following use of this dangerous drug," said House Values Action Team Chairman Robert Aderholt. "Even more troubling, a recent large-scale study shows significant under-reporting of these adverse events. I urge HHS to quickly expedite its thorough investigation into the harmful effects and adverse events associated with mifepristone, as already promised by Secretary Kennedy. We must protect women from the dangers and serious risks of chemical abortion."

“By approving another generic iteration of this pill while a safety review is ongoing, the FDA risks undermining women’s health and safety across the United States. The agency must stay true to its mission of protecting public health and ensuring the safety of drugs,” Congressman Aderholt added. “As always, I remain committed to working with my colleagues in Congress and across the government to better protect the lives of women and the unborn from these dangerous drugs.”

"The FDA's approval of another version of the abortion pill, mifepristone, raises serious concerns. This drug has well-documented risks to women's health and is responsible for ending the lives of innocent unborn children. I urge the agency to carefully reconsider this decision and remain committed to its mission to protect public health, uphold the sanctity of life, and ensure the safety of all approved medications,” said House VAT Co-Chair Rep. Mary Miller (IL-15).

“The FDA’s recent approval of the generic version of mifepristone, the abortion pill, is completely unacceptable. Abortion is one of the defining evils of our time, and we must acknowledge that it is murder in every form.  HHS must take accountability for this approval and thoroughly look into the negative effects of mifepristone, and its generic counterpart, not only on the children it murders but on the women who take it. Despite being labeled as ‘safe,’ 1 in 10 women who take the abortion pill face serious complications, at a rate 22x higher than initially reported by the FDA. How can anyone consider this safe?” said House VAT Co-Chair Rep. Josh Brecheen (OK-04).

“Chemical abortion is not health care, and the Biden–Harris policy that stripped essential safety standards must be reversed. By expanding mifepristone access without in-person medical oversight and by permitting mail-order and retail pharmacy dispensing, their administration put women and unborn children at unnecessary risk. HHS should act immediately to reinstate these protections and complete its review so the public has the full picture of risks and outcomes. That is why I have introduced legislation in each of the last two Congresses to nullify the Biden-Harris administration’s dangerous mifepristone policy changes and restore common-sense safeguards for mothers and their babies,” said VAT Executive Committee Member Congresswoman Diana Harshbarger.

“The approval of a generic abortion pill is a grim development for the most vulnerable members of our society, the unborn, and the mothers who take it,” said VAT Executive Committee Member Congressman John Moolenaar (MI-02). “Chemical abortion drugs now account for a majority of abortions in the United States and are proven to come with significant medical risks and dangerous side effects. More should be done to protect the sanctity of life, help women through pregnancy with resources to have healthy babies, and stop dangerous drugs that could hurt them from coming into the market.”

"Every heartbeat is a miracle that deserves protection,” said VAT Executive Committee Member Congressman Mark Alford (MO-04). “The FDA’s approval of yet another chemical abortion drug is a heartbreaking step in the wrong direction. We believe in life-affirming care for the mother and the child that God is growing inside of her. Instead of promoting dangerous drugs that end life, we should be supporting women with compassion, resources, and hope. A nation that values life at every stage is a nation that values its future, and I will never stop fighting to defend it.”

"As a medical provider, I find the FDA’s approval of another abortion pill is reckless and politically driven. Mifepristone has a well-documented record of dangerous side effects, yet unelected bureaucrats continue to push it forward,” said Congresswoman Sheri Biggs (SC-03). “I’m committed to reining in the swamp and restoring accountability to protect women and the unborn."

“I urge HHS to move quickly and keep its word by conducting a full and transparent investigation into the harmful effects and adverse events linked to mifepristone, as Secretary Kennedy has already promised. This dangerous drug has been marketed as ‘safe,’ yet it has left a trail of pain, complications, and even death. Beyond the physical risks, we must also remember what’s at stake spiritually and morally. Every dose of mifepristone is designed to end an innocent human life, a life made in the image of God. As a nation, we cannot turn a blind eye to both the harm done to mothers and the tragic loss of children. I will continue to fight for the truth, for accountability, and most importantly, for the sanctity of life,” said Congressman Barry Moore (AL-01).

"The approval of yet another abortion pill not only endangers women's health but shows blatant disregard for human life. Instead of rushing dangerous chemical abortions to market, federal agencies should be focused on protecting women and safeguarding the unborn,” said Congressman Andy Biggs (AZ-05).

“The FDA’s approval of a new generic version of the chemical abortion drug mifepristone puts both women’s health and the right to life in danger,” said Congressman Daniel Webster (FL-11). “Our nation’s health agencies have a responsibility to protect life, not expand the reach of drugs that end it while placing women’s health at risk. I join my colleagues in calling on HHS to expedite its investigation into the harmful effects of chemical abortion drugs. Life is our most precious gift, and I will not waiver in my defense of the sanctity of life.”

“Life begins at conception. Chemical abortion kills unborn children and harms mothers,” said Congressman Riley M. Moore (WV-02) in response to the FDA’s approval of a new generic version of mifepristone. “By approving this generic drug while actively reviewing the mounting evidence that mifepristone should never have been approved in the first place, the FDA is recklessly endangering women’s health and dismissing the sanctity of human life. I urge the FDA and HHS Secretary Robert F. Kennedy Jr. to reverse course immediately and halt the distribution of this life-ending drug.”

“Thomas Jefferson wisely said, ‘The first duty of government is the protection of life, not its destruction. Abandon that, and you have abandoned all.’ Approving new generic versions of mifepristone fails the government’s duty to protect innocent life, a principle I will never abandon,” said Congressman Randy Weber (TX-14). “As a member of the House Values Action Team, I join those urging Secretary Kennedy to expedite the review of the effects linked to mifepristone use. These serious effects carry dangerous consequences for mothers and children – their safety must be at the forefront as this review moves forward.”

“The approval of the generic version of the chemical abortion drug mifepristone is deeply concerning. This new version was approved under the same weakened standards the previous administration applied to mifepristone, which removed critical safeguards designed to protect women’s health and safety,” said Congressman August Pfluger (TX-11). “Mifepristone has a well-documented record of serious medical complications, with countless women suffering severe health consequences or even losing their lives. Compounding these risks, some abusers and human traffickers have taken advantage of these lowered standards and mail-order access to obtain the pills without medical oversight or verification, in some cases giving them to women without their knowledge or consent. Approving this generic version under these same reckless standards only expands these dangers and puts more women and their unborn children at risk. I remain committed to protecting life, defending women’s health and safety, and ensuring Secretary Kennedy remains committed to restoring safeguards on these dangerous abortion drugs.”

“Chemical abortion is becoming more common throughout the United States. In addition to taking the lives of unborn children, the dangerous nature of the chemical abortion drug mifepristone creates a serious risk to the lives of women. The lack of oversight surrounding mail-order abortion pills has the potential to create very serious side effects for women. I appreciate Secretary Kennedy’s attention to this issue and his continuing to ensure the safety of women by keeping them informed of the harmful nature of mifepristone," said Congressman Michael Guest (MS-03).

“The Food and Drug Administration's (FDA) recent approval of a generic version of mifepristone—a lethal abortion drug currently under review by the agency—is reprehensible and should be reversed immediately. Mifepristone is used in over 60% of U.S. abortions and has a track record of severe complications, including life-threatening risks to women and the guaranteed loss of unborn lives. Expanding access to a drug linked to countless tragedies is indefensible. In order to prioritize safety and the sanctity of life, the FDA should pull all versions of mifepristone from the market immediately, not flood our mailboxes with it," said Congressman Keith Self (TX-03).

“The FDA’s rush to approve another version of mifepristone endangers women’s health and disregards the value of life. This drug has a well-documented history of serious complications,” said Congressman Bob Onder (M0-03). “The FDA should be protecting women and the unborn, not rushing to expand access to dangerous chemical abortions.” 

“Mifepristone kills and endangers women’s health. It is alarming that a new variation of this life-terminating drug was approved while a safety review of its dangerous health implications is under review,” said Congressman Russ Fulcher (ID-01). “All life is precious, and I will continue to do everything I can in Congress to protect both expecting mothers and the unborn.”

“The FDA’s approval of yet another generic abortion pill is reckless and deeply troubling. These drugs aren’t safe, and no amount of political spin can change that. Studies from the Charlotte Lozier Institute show that chemical abortions, now the most prevalent form of abortion, dramatically increase the risk of an emergency room visit. We’ve seen tragic cases of severe complications, hemorrhaging, infections, and even death. I will never apologize for standing up for life—both the life of the unborn child and the well-being of the mother. The FDA should be protecting women and babies, not putting them in harm’s way,” said Congressman Brian Babin, D.D.S. (TX-36).

“Now that the FDA has approved a new generic abortion pill, it is imperative that the review of the dangers surrounding Mifepristone be completed as soon as possible. I implore the FDA to consider the complications involved in the unsupervised use of the abortion pill and consider requiring in-person dispensing of any drug such as this that has a record of causing severe adverse effects for the receiver,” said Congressman Mark Messmer (IN-08).

“Every life is a gift from God and must be protected. The approval of another generic version of mifepristone while a safety review is being conducted will put the health and lives of women and girls at risk across the country and undercuts the goal of saving every life possible. I urge the FDA to complete its review, and to do all possible protect the well-being of women and the unborn,” said Congressman Nathaniel Moran (TX-01).

“The FDA’s decision to approve yet another version of mifepristone, a dangerous abortion drug, is deeply troubling,” said Congressman Glenn Grothman (WI-06). “This decision not only puts women’s health at risk but further normalizes a culture that devalues human life. Instead of expanding access to chemical abortions, the FDA should be focused on protecting public health and promoting real support for mothers and families. Every life, born and unborn, deserves dignity and care.”

“I am proud that Arkansas has already decided to protect life from the moment of conception and protect women from dangerous abortion pills. Sadly, unscrupulous actors from other states dump abortion pills into Arkansas, with no regard to our duly enacted laws or the well-being of unborn children and vulnerable women. Unfortunately, the FDA’s approval of this generic abortion drug will only make this problem worse,” said Congressman Rick Crawford (AR-01).  I stand with Values Action Team Chairman Aderholt and urge HHS to expedite its safety review of the dangerous effects of Mifepristone and encourage the administration to continue its strong enforcement of pro-life policies, including the Hyde Amendment and the Mexico City Policy.”

“Whether over-the-counter or at the clinic, aborting a child is a soulless, demonic act,” said Congressman Marlin Stutzman (IN-03). “My heart aches for the children who will now face death because the FDA decided our country needed a more efficient route to extinguish the lives of our most vulnerable. I pray that this decision is swiftly reversed.”